ATE536870T1 - N-acetyl-l-cystein zur behandlung von endometriose - Google Patents

N-acetyl-l-cystein zur behandlung von endometriose

Info

Publication number
ATE536870T1
ATE536870T1 AT09171394T AT09171394T ATE536870T1 AT E536870 T1 ATE536870 T1 AT E536870T1 AT 09171394 T AT09171394 T AT 09171394T AT 09171394 T AT09171394 T AT 09171394T AT E536870 T1 ATE536870 T1 AT E536870T1
Authority
AT
Austria
Prior art keywords
treatment
endometriosis
nac
reduce
cystein
Prior art date
Application number
AT09171394T
Other languages
English (en)
Inventor
Tiziana Parasassi
Maria Grazia Porpora
Original Assignee
Iasomai Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iasomai Aktiebolag filed Critical Iasomai Aktiebolag
Application granted granted Critical
Publication of ATE536870T1 publication Critical patent/ATE536870T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AT09171394T 2009-09-25 2009-09-25 N-acetyl-l-cystein zur behandlung von endometriose ATE536870T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09171394A EP2305238B1 (de) 2009-09-25 2009-09-25 N-acetyl-L-cystein zur Behandlung von Endometriose

Publications (1)

Publication Number Publication Date
ATE536870T1 true ATE536870T1 (de) 2011-12-15

Family

ID=41396460

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09171394T ATE536870T1 (de) 2009-09-25 2009-09-25 N-acetyl-l-cystein zur behandlung von endometriose

Country Status (11)

Country Link
US (1) US8637573B2 (de)
EP (1) EP2305238B1 (de)
JP (1) JP5699396B2 (de)
CN (3) CN102665707A (de)
AT (1) ATE536870T1 (de)
AU (1) AU2010299801B2 (de)
DK (1) DK2305238T3 (de)
ES (1) ES2382167T3 (de)
PL (1) PL2305238T3 (de)
RU (1) RU2549433C2 (de)
WO (1) WO2011036265A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE536870T1 (de) 2009-09-25 2011-12-15 Iasomai Aktiebolag N-acetyl-l-cystein zur behandlung von endometriose
WO2012130646A1 (en) 2011-03-25 2012-10-04 Iasomai Ab N-acetyl-l-cysteine for the treatment of dysmenorrhea
EP2694045B1 (de) 2011-04-01 2019-10-30 Iasomai AB Neue kombination mit n-acetyl-l-cystein und ihre verwendung
RU2641606C2 (ru) 2012-11-09 2018-01-18 Иасомай АБ N-ацетил-L-цистеин для применения в экстракорпоральном оплодотворении
EP2789345A1 (de) * 2013-04-09 2014-10-15 Pizeta Group S.r.l. Zusammensetzung zur Behandlung von Endometriose
CN104856996B (zh) * 2015-04-27 2018-01-05 南京舒鹏生物科技有限公司 吡咯喹啉醌、其衍生物和/或盐新的药用用途以及药用组合物
RU2597845C1 (ru) * 2015-06-25 2016-09-20 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ улучшения рецептивности эндометрия у пациенток с бесплодием, ассоциированным с эндометриозом
CN110151783A (zh) * 2019-02-02 2019-08-23 复旦大学附属妇产科医院 一种用于预防子宫内膜异位症复发的腹腔冲洗液
RU2711615C1 (ru) * 2019-09-12 2020-01-17 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт акушерства, гинекологии и репродуктологии имени Д.О. Отта" Способ лечения эндометриоза на основании экспериментальной модели у крыс
AU2022217222A1 (en) * 2021-02-02 2023-08-10 Guangzhou Hutongyouwu Biotechnology Co., Ltd New use of pqq and derivative thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE278399T1 (de) 1995-07-21 2004-10-15 Savvipharm Inc Orotatsalze von 5-amino- oder substituierten amino-1,2,3-triazolen zur behandlung von neoplasmen
US20040122011A1 (en) 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US7122203B2 (en) 2000-05-08 2006-10-17 Eli Lilly And Company Stabilized formulations of 6-hydroxy-3-(-4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene and salts thereof
CZ20031098A3 (cs) 2000-10-20 2003-08-13 Eli Lilly And Company Nová krystalická forma 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]fenoxy)-2-(4-methoxyfenyl)benzo[b]thiofen hydrochloridu
US20030190381A1 (en) 2001-02-02 2003-10-09 Bland Jeffrey S. Medical composition for balancing bodily processes
WO2005048822A2 (en) 2003-11-18 2005-06-02 Attenuon Llc Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
US20070287676A1 (en) 2006-05-16 2007-12-13 Sun-Wei Guo Diagnosis and treatment of endometriosis
ATE536870T1 (de) 2009-09-25 2011-12-15 Iasomai Aktiebolag N-acetyl-l-cystein zur behandlung von endometriose

Also Published As

Publication number Publication date
CN106974900A (zh) 2017-07-25
AU2010299801B2 (en) 2016-06-30
CN107007584A (zh) 2017-08-04
JP5699396B2 (ja) 2015-04-08
WO2011036265A1 (en) 2011-03-31
ES2382167T3 (es) 2012-06-06
JP2013505916A (ja) 2013-02-21
US8637573B2 (en) 2014-01-28
PL2305238T3 (pl) 2012-07-31
AU2010299801A1 (en) 2012-04-19
RU2549433C2 (ru) 2015-04-27
CN102665707A (zh) 2012-09-12
EP2305238A1 (de) 2011-04-06
US20120238627A1 (en) 2012-09-20
DK2305238T3 (da) 2012-03-26
RU2012116441A (ru) 2013-10-27
EP2305238B1 (de) 2011-12-14

Similar Documents

Publication Publication Date Title
DK2305238T3 (da) N-acetyl-L-cystein til behandling af endometriose
PH12012501067A1 (en) Combination therapy for treating cancer and diagnostic assays for use therein
MX364874B (es) Anticuerpos de il-6 y uso de los mismos.
BR112014014783A2 (pt) moléculas de inibidor de jnk para tratamento de várias doenças
MY197091A (en) Compositions for treating acid-base disorders
ATE553719T1 (de) Vorrichtung zur unterstützung eines vaginalcuffs
BR112013017446A2 (pt) composição, uso de dose baixa de pioglitazona, método de tratar a deterioração cognitiva do tipo de alzheimer em um indivíduo humano, de tratar o declínio cognitivo em um indivíduo humano, de determinar o risco aumentado de desenvolver a deterioração cognitiva do tipo de alzheimer em um indivíduo humano em uma uma idade ou faixa de idade pré-determinadas, de determinar se administrar dose baixa de pioglitazona a um indivíduo humano para o tratamento da deterioração congnitiva do tipo de alzheimer, de retardar o início da doença de alzheimer em um indivíduo em risco de desenvolver a doença alzheimer, de retardar o início da deterioração cognitiva amnésia branda em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pré-clínica em um indivíduo em risco de desenvolver a doença de alzheimer, de retardar o início da doença de alzheimer pródroma em um indivíduo em risco de desenvolver a doença de alzheimer, dose baixa de pioglitazona
EA201300133A1 (ru) Фармацевтическая композиция и способ лечения ожирения, сопутствующих метаболических расстройств и зависимости от психоактивных веществ
SA521421680B1 (ar) نظام وطريقة وجهاز لعلاج محسن للارتجاع المعدي المريئي
GT200600115A (es) Metodo para identificar blancos terapeuticos para el tratamiento de atrofia vulvoginal
ATE380554T1 (de) Verwendung von xenon mit hypothermie zur behandlung von neugeborenen-asphyxie
DE602006011959D1 (de) Na+, k+-atpase-expression bei zervixdysplasie und -krebs
WO2011084791A3 (en) Early marker of proteinuria in patients treated with an anti-vegf treatment
CY1110239T1 (el) Χρηση ακετυλο-l-kapnιτινη σε συνδυασμο με προπιονυλο-l-καρνιτινη και σιλδεναφιλη για τη θεραπευτικη αγωγη της στυτικης δυσλειτουργιας
CN202191280U (zh) 振动加载实验装置
EP2560674A4 (de) Nanopartikel-targeting von ischämie für bildgebung und therapie
RU2010135846A (ru) Способ лечения болезни келлер-1
Abaeva et al. FERMENTATIVNYE ASPEKTY PATOGENEZA PROLAPSA GENITALIY
RU2009119225A (ru) Способ лечения и профилактики кокцидиозов норок
Domazcii et al. DOGS AND CATS TOXOCARIASIS IN URBANFOCIOF WEST SIBERIA
Schaafsma et al. Constitutive Inhibition Of PKA Activity Suppresses Human Airway Smooth Muscle Maturation
Hmid et al. Evaluation of different techniques for vaginoplasty in the treatment of the syndrome of Mayer-Rokitansky-Küster-Hauser
BR112012017135A2 (pt) biomarcadores de efeitos imunoduladores em seres humanos tratados com anticorpos anti-cd200.
Joshi Dabrafenib/trametinib
Krishnappa et al. Turner Syndrome